Although
hypoxia has been shown to reprogram
cancer cells toward glycolytic shift, the identity of extrinsic stimuli that induce metabolic reprogramming independent of
hypoxia, especially in
ovarian cancer, is largely unknown. In this study, we use patient-derived
ovarian cancer cells and high-grade serous
ovarian cancer cell lines to demonstrate that
lysophosphatidic acid (LPA), a
lipid growth factor and GPCR
ligand whose levels are substantially increased in
ovarian cancer patients, triggers glycolytic shift in
ovarian cancer cells. Inhibition of the
G protein α-subunit Gαi2 disrupted LPA-stimulated aerobic glycolysis. LPA stimulated a pseudohypoxic response via Rac-mediated activation of
NADPH oxidase and generation of
reactive oxygen species, resulting in activation of HIF1α. HIF1α in turn induced expression of
glucose transporter-1 and the glycolytic
enzyme hexokinase-2 (HKII). Treatment of mice bearing
ovarian cancer xenografts with an HKII inhibitor,
3-bromopyruvate, attenuated
tumor growth and conferred a concomitant survival advantage. These studies reveal a critical role for LPA in metabolic reprogramming of
ovarian cancer cells and identify this node as a promising therapeutic target in
ovarian cancer.Significance: These findings establish LPA as a potential therapeutic target in
ovarian cancer, revealing its role in the activation of HIF1α-mediated metabolic reprogramming in this disease.
Cancer Res; 78(8); 1923-34. ©2018 AACR.